UBS, Stifel start coverage of BioVersys with 'buy;' shares climb

Swiss biotech firm BioVersys BIOV.S shares up 4.3% to 36.2 Swiss francs at 1402 GMT

UBS starts coverage with "buy" rating and PT of 48 francs; Stifel also starts with "buy" and PT of 70 francs

UBS says the market does not fully reflect the "high probability of success" of the late stage trial data for co's lung infection drug BV100, due in H2 of 2027

Estimates $430 mln in unadjusted peak sales for BV100, with a 70% probability of success

If late-stage trial data shows superiority to Colistin, an antibiotic used to treat serious infections, and BIOV finds a strong partner, it could make up to $370 mln unadjusted peak sales just from China alone in RoW - brokerage

*Stifel notes that BioVersys is boasting a well-advanced pipeline that could start delivering as soon as 2028 with its two lead assets, BV100 and tuberculosis product alpibectir, having completed their phase 2 of clinical developments

It adds that "strong partner" GSK is expanding its collaboration beyond current phase 2a study on alpibectir and supported the company's IPO earlier this year

It forecasts peak sales of 1.2 billion francs for both BV100 and alpibectir and adds BV100 could arrive on the US market in 2028, followed by alpibectir in 2030